Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG has shown promising advancements in its pipeline, particularly with OCS-05, which is moving towards registrational trials for acute optic neuritis and exploratory Phase 2 trials in other neuro-ophthalmic disorders, indicating the company's commitment to expanding its treatment capabilities. Positive clinical outcomes, such as a notable gain of 7.6 letters in Best Corrected Visual Acuity (BCVA) at 12 weeks for OCS-01, suggest that the company's products may secure a significantly larger market share than currently modeled. Additionally, the enthusiasm expressed by key opinion leaders and physicians regarding the neuroprotective potential of Oculis's therapies further solidifies a positive outlook for the company as it prioritizes and advances its innovative drug candidates.

Bears say

The financial outlook for Oculis Holding appears negative due to significant delays in clinical development and potential regulatory hurdles that could prolong timelines and inflate operational costs. The absence of data catalysts until the second quarter of 2026 has contributed to investor skepticism, limiting market interest and participation. Additionally, increasing competition from other therapies targeting Oculis's indications may hinder market penetration and affect pricing strategies, further complicating the company’s growth potential.

OCS has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 4 analysts, OCS has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.